Thrivent Financial for Lutherans’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-70,641	Closed	-$82K	–	2645
2025 Q2	$82K	Hold	70,641	–	–	﹤0.01%	2414
2025 Q1	$112K	Hold	70,641	–	–	﹤0.01%	2342
2024 Q4	$214K	Buy	70,641 +43,036	+156%	+$141K	﹤0.01%	2502
2024 Q3	$101K	Hold	27,605	–	–	﹤0.01%	2497
2024 Q2	$112K	Sell	27,605 -1,181	-4%	-$13.2K	﹤0.01%	2504
2024 Q1	$454K	Hold	28,786	–	–	﹤0.01%	2266
2023 Q4	$436K	Sell	28,786 -1,406	-5%	-$20.5K	﹤0.01%	2242
2023 Q3	$605K	Hold	30,192	–	–	﹤0.01%	2044
2023 Q2	$852K	Sell	30,192 -1,482	-5%	-$35.6K	﹤0.01%	1912
2023 Q1	$544K	Hold	31,674	–	–	﹤0.01%	2095
2022 Q4	$638K	Hold	31,674	–	–	﹤0.01%	1995
2022 Q3	$687K	Hold	31,674	–	–	﹤0.01%	1912
2022 Q2	$890K	Buy	+31,674	New	+$839K	﹤0.01%	1781

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thrivent Financial for Lutherans's ZNTL Position: Q3 2025 in Review

Thrivent Financial for Lutherans sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 70,641 shares — an estimated $82K sold.

Thrivent Financial for Lutherans first reported a position in ZNTL in Q2 2022 and held it in 13 quarters. The position peaked at $890K in Q2 2022. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Thrivent Financial for Lutherans reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Thrivent Financial for Lutherans sold 70,641 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $82K.
Thrivent Financial for Lutherans first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 13 quarters.
Thrivent Financial for Lutherans's Zentalis Pharmaceuticals position peaked at $890K in Q2 2022.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2025, filed 4 Nov 2025.